Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis

Efficacy of PD-1/PD-L1 Inhibitors versus Chemotherapy in Lung Cancer with Brain Metastases: A Systematic Review and Meta-Analysis

Immune checkpoint inhibitors (ICIs) are widely used to treat local or metastatic lung cancer. However, the efficacy of ICI in patients with brain metastases (BM) from lung cancer is unknown. This study aimed to evaluate the efficacy of PD-1/PD-L1 ICIs compared with chemotherapy for patients with lun...

Full description

Saved in:

Bibliographic Details
Main Authors:	Xiaojun Yang, Yihong Zeng, Qinquan Tan, Zhihua Huang, Jun Jia, Guanming Jiang
Format:	Article
Language:	English
Published:	Wiley 2022-01-01
Series:	Journal of Immunology Research
Online Access:	http://dx.doi.org/10.1155/2022/4518898
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Updated Bayesian network meta-analysis on the efficacy and safety of PD−1 versus PD−L1 inhibitors in first−line treatment with chemotherapy for extensive−stage small-cell lung cancer
by: Ke Wang, et al.
Published: (2025-01-01)

Comparison of the Efficacy and Safety of PD‐1/PD‐L1 Inhibitors in the Treatment of Small Cell Lung Cancer
by: Qichen Zhang, et al.
Published: (2025-01-01)

Hepatic arterial infusion chemotherapy combined with lenvatinib and PD-1 inhibitors versus lenvatinib and PD-1 inhibitors for unresectable HCC: a meta-analysis
by: Min Wei, et al.
Published: (2024-12-01)

Ocular adverse events in PD-1 and PD-L1 inhibitors
by: James Murray, et al.
Published: (2021-07-01)

Propensity score–weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non–small cell lung cancer (WJOG10217L)
by: Nobuyuki Yamamoto, et al.
Published: (2020-05-01)

Efficacy and safety of combining anti-angiogenic therapy, radiotherapy, and PD-1 inhibitors in patients with driver gene-negative non-small cell lung cancer brain metastases: a retrospective study
by: Xianwen Zhang, et al.
Published: (2024-12-01)

A network comparison on efficacy and safety profiling of PD-1/PD-L1 inhibitors in first-line treatment of advanced non-small cell lung cancer
by: Jie Fu, et al.
Published: (2025-01-01)

Efficacy of PD-1 blockade plus chemotherapy in patients with oncogenic-driven non-small-cell lung cancer
by: Haowei Wang, et al.
Published: (2025-02-01)

Association of metabolomics with PD-1 inhibitor plus chemotherapy outcomes in patients with advanced non-small-cell lung cancer
by: Jun Lu, et al.
Published: (2024-04-01)

The efficacy and safety of PD-1 inhibitors combined with chemotherapy treatment for advanced esophageal cancer: a network meta-analysis
by: Jian-Zhou Tian, et al.
Published: (2025-01-01)

Efficacy and safety of first-line PD-1/PD-L1 inhibitor in combination with CTLA-4 inhibitor in the treatment of patients with advanced non-small cell lung cancer: a systemic review and meta-analysis
by: Huimin Zhao, et al.
Published: (2025-02-01)

A computational chemistry-based approach to optimizing PD-1/PD-L1 inhibitors
by: Meijuan Zhai, et al.
Published: (2025-01-01)

Optimizing PD-L1/PD-1 therapies: Immune checkpoint inhibitors in nasopharyngeal carcinoma
by: Madhan Krishnan, et al.
Published: (2024-12-01)

Efficacy of neoadjuvant PD-1/PD-L1 inhibitor in resectable NSCLC: a meta-analysis based on randomized controlled trials
by: Weiming Zhang, et al.
Published: (2024-12-01)

Efficacy and safety of PD-1 and PD-L1 inhibitors in advanced colorectal cancer: a meta-analysis of randomized controlled trials
by: Zhenzi Wang, et al.
Published: (2024-12-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in patients with Merkel Cell Carcinoma: a systematic review and Meta-analysis
by: Francisco Cezar Aquino de Moraes, et al.
Published: (2024-11-01)

Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer
by: Marta Zayas-Soriano, et al.
Published: (2021-01-01)

Bibliometric analysis of the research landscape of PD-1/PD-L1 inhibitors in the treatment of bowel cancer
by: Qingwei Luo, et al.
Published: (2025-02-01)

Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy
by: Madhusudan Roy, et al.
Published: (2024-03-01)

The clinical value of local consolidative therapy for oligo-residual disease in PD-1/PD-L1 inhibitors-treated non-small cell lung cancer
by: Yuqi Su, et al.
Published: (2024-12-01)

Perioperative PD-1/PD-L1 inhibitors for resectable non-small cell lung cancer: A meta-analysis based on randomized controlled trials.
by: Hai Huang, et al.
Published: (2024-01-01)

Efficacy and Safety of Transcatheter Arterial Chemoembolization Combined with Lenvatinib Plus Anti-PD-1 Inhibitors for Hepatocellular Carcinoma Patients with Extrahepatic Metastases: A Multicenter Retrospective Study
by: Liu DY, et al.
Published: (2024-11-01)

Improving PD-1 blockade plus chemotherapy for complete remission of lung cancer by nanoPDLIM2
by: Fan Sun, et al.
Published: (2024-12-01)

PD-1/PD-L1 inhibitors related adverse events: A bibliometric analysis from 2014 to 2024
by: Qingya Song, et al.
Published: (2025-12-01)

Identification of novel PD-1/PD-L1 small molecule inhibitors: virtual screening, synthesis and in vitro characterisation
by: Tingting Wu, et al.
Published: (2024-12-01)

Risk of immune‐related pneumonitis for PD1/PD‐L1 inhibitors: Systematic review and network meta‐analysis
by: Yafang Huang, et al.
Published: (2019-05-01)

The efficacy and safety of a taxane-based chemotherapy regimen combined with a PD-1 inhibitor in HNSCC: a multicenter real-world study
by: Min Ouyang, et al.
Published: (2025-01-01)

Letter to the editor, “Depth-dependent PD-L1 sampling of head and neck squamous cell carcinoma (HNSCC) – Implications for PD-1/PD-L1 checkpoint inhibitor immunotherapy.”
by: Geetha Shanmugam
Published: (2024-09-01)

Efficacy and safety of PD-1/PD-L1 inhibitors in advanced or recurrent endometrial cancer: a meta-analysis with trial sequential analysis of randomized controlled trials
by: Ji Ren, et al.
Published: (2025-01-01)

Use of a PD-1 checkpoint inhibitor in a patient with ultra-high-risk gestational trophoblastic neoplasia and gastrointestinal metastases
by: Amalia Brawley, et al.
Published: (2024-12-01)

Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice
by: Alessandro Russo, et al.
Published: (2020-10-01)

Safety and efficacy of PD-1/PD-L1 immune checkpoint inhibitors in patients with pre-treated advanced stage malignant mesothelioma: a systematic review and meta-analysis
by: Amjad Zafar, et al.
Published: (2024-11-01)

Comparison of treatment outcome between first‐line combination immunotherapy (anti‐PD‐L1 or anti‐PD1) with or without chemotherapy and chemotherapy alone in advanced non‐small cell lung cancer patients in tertiary care hospital
by: Danainut Naratornsirakul, et al.
Published: (2024-07-01)

Development of diffuse cutaneous squamous cell carcinoma in situ after chemotherapy for ovarian carcinoma and remission with PD1-inhibitor
by: Jess Durbin, et al.
Published: (2024-12-01)

Enhancing immunotherapy through PD‐L1 upregulation: the promising combination of anti‐PD‐L1 plus mTOR inhibitors
by: Anna Hernández‐Prat, et al.
Published: (2025-01-01)

Progression patterns in patients with advanced hepatocellular carcinoma treated with local therapy, targeted drugs, and PD-1/PD-L1 inhibitors
by: Yanan Zhao, et al.
Published: (2024-08-01)

Comparison of iRECIST versus RECIST V.1.1 in patients treated with an anti-PD-1 or PD-L1 antibody: pooled FDA analysis
by: Flora Mulkey, et al.
Published: (2020-05-01)

Follicular helper-T cells restore CD8+-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy
by: Francois Ghiringhelli, et al.
Published: (2021-06-01)

PD-1/PD-L1 Inhibitors Plus Antiangiogenic Drugs Versus Sorafenib as the First Line Treatment for Advanced Hepatocellular Carcinoma: A Phase 3 RCTs Based Meta-Analysis
by: Jun Li MD, et al.
Published: (2024-12-01)

Noninvasive Imaging of Immune Checkpoint Ligand PD-L1 in Tumors and Metastases for Guiding Immunotherapy
by: Samit Chatterjee PhD, et al.
Published: (2017-07-01)